Investing.com -- Morgan Stanley downgraded Enfusion Inc (NYSE:ENFN) stock to "Equal-weight" from "Overweight" following Clearwater Analytics' proposed $1.5 billion acquisition at $11.25 per share.
With the bid accelerating value realization, Morgan Stanley (NYSE:MS) raised its price target by 25 cents to $11.25, in line with the offer price.
“One of the central tenets of our historical Overweight thesis was predicated on untapped strategic value that resulted in minimal absolute downside and an asymmetric risk-reward. With CWAN's proposed acquisition of Enfusion at $11.25, strategic value has been unlocked and we step to the sidelines,” Morgan Stanley analyst wrote.
The offer represents a 13% premium to Enfusion's most recent closing price and a 32% premium to its September 2024 levels.
Morgan Stanley noted that the deal unlocks strategic value for shareholders and addresses longstanding challenges such as limited stock float and a high concentration of startup hedge fund clients.
MS added it had long held the view on Enfusion as a strategically valuable asset, burdened by limited public float.
Related Articles
MS cuts rating on Enfusion stock after Clearwater’s acquisition bid
Biden administration to revoke Cuba's terrorism sponsor designation
Apple, Amazon fight off $600 million UK lawsuit over alleged 'collusion'
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。